Paul Peter Tak, M.D., Ph.D., FMedSci
2020
In 2020, Paul Peter Tak, M.D., Ph.D., FMedSci earned a total compensation of $2.6M as President and Chief Executive Officer at Candel Therapeutics.
Compensation breakdown
| Bonus | $85,000 |
|---|---|
| Non-Equity Incentive Plan | $90,450 |
| Option Awards | $2,316,446 |
| Salary | $134,615 |
| Total | $2,626,511 |
FMedSci received $2.3M in option awards, accounting for 88% of the total pay in 2020.
FMedSci also received $85K in bonus, $90.5K in non-equity incentive plan and $134.6K in salary.
Rankings
In 2020, Paul Peter Tak, M.D., Ph.D., FMedSci's compensation ranked 4,357th out of 13,090 executives tracked by ExecPay. In other words, FMedSci earned more than 66.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,357 out of 13,090 | 67th |
Division Manufacturing | 1,768 out of 5,618 | 69th |
Major group Chemicals And Allied Products | 691 out of 2,251 | 69th |
Industry group Drugs | 591 out of 1,951 | 70th |
Industry Biological Products, Except Diagnostic Substances | 136 out of 411 | 67th |
Source: SEC filing on September 2, 2022.
FMedSci's colleagues
We found two more compensation records of executives who worked with Paul Peter Tak, M.D., Ph.D., FMedSci at Candel Therapeutics in 2020.